Related Experiment Videos
The effect of lidoflazine on ventricular ectopic activity in chronic ischaemic heart disease
Insights
Lidoflazine effectively reduced ventricular ectopic beats in patients with ischemic heart disease. Further research is recommended for its anti-anginal and anti-arrhythmic potential.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Chronic ischemic heart disease is often associated with myocardial infarctions and ventricular arrhythmias.
- Frequent ventricular ectopic beats are a significant risk factor in patients with ischemic heart disease.
Purpose of the Study:
- To evaluate the efficacy of lidoflazine in managing chronic ischemic heart disease.
- To assess lidoflazine's effect on ventricular ectopic beats in high-risk patients.
- To explore lidoflazine's potential as both an anti-anginal and anti-arrhythmic agent.
Main Methods:
- A study involving 11 patients with chronic ischemic heart disease and a history of myocardial infarction.
- Patients were monitored for up to 23 months.
- Holter tape recordings were conducted every 4 weeks to assess ventricular ectopic beat frequency.
Main Results:
- Lidoflazine significantly decreased the frequency of ventricular ectopic beats in 7 out of 11 patients.
- One patient experienced a recurrent acute myocardial infarction.
- Two patients died from presumed cardiogenic causes; drug causation was not definitively excluded.
Conclusions:
- Lidoflazine demonstrates potential as a ventricular anti-arrhythmic agent in patients with ischemic heart disease.
- The observed reduction in ventricular ectopic beats warrants further investigation into lidoflazine's therapeutic applications.
- Continued research is justified to confirm lidoflazine's efficacy and safety profile.
Abstract:
The efficacy of lidoflazine was evaluated in 11 patients with chronic ischaemic heart disease. All patients had suffered one or more myocardial infarctions and all were bad risk patients with frequent ventricular ectopic beats. The patients were followed for periods of up to 23 months and 6-7 Holter tape recordings were performed at 4-weekly intervals. The frequency of ventricular ectopic beats decreased in 7 and remained unchanged in only 1 patient. One patient developed a recurrent acute myocardial infarction and 2 patients died, presumably of cardiogenic cause, but drug causation could not be excluded. It is concluded that the results justify further study of lidoflazine, not only as an anti-anginal but also as a ventricular antidysrhythmic agent.